Prothrombin time is predictive of low plasma prothrombin concentration and clinical outcome in patients with trauma hemorrhage: analyses of prospective observational cohort studies
- Clare A. Balendran†1Email author,
- Ann Lövgren†2, 4,
- Kenny M. Hansson2,
- Karin Nelander3,
- Marita Olsson3,
- Karin J. Johansson2,
- Karim Brohi5,
- Dietmar Fries6 and
- Anders Berggren3
© The Author(s). 2016
Received: 21 July 2016
Accepted: 18 November 2016
Published: 14 March 2017
Fibrinogen and prothrombin have been suggested to become rate limiting in trauma associated coagulopathy. Administration of fibrinogen is now recommended, however, the importance of prothrombin to patient outcome is unknown.
We have utilized two trauma patient databases (database 1 n = 358 and database 2 n = 331) to investigate the relationship of plasma prothrombin concentration on clinical outcome and coagulation status. Database 1 has been used to assess the relationship of plasma prothrombin to administered packed red blood cells (PRBC), clinical outcome and coagulation biomarkers (Prothrombin Time (PT), ROTEM EXTEM Coagulation Time (CT) and Maximum Clot Firmness (MCF)). ROC analyses have been performed to investigate the ability of admission coagulation biomarkers to predict low prothrombin concentration (database 1), massive transfusion and 24 h mortality (database 1 and 2). The importance of prothrombin was further investigated in vitro by PT and ROTEM assays in the presence of a prothrombin neutralizing monoclonal antibody and following step-wise dilution.
Patients who survived the first 24 h had higher admission prothrombin levels compared to those who died (94 vs.67 IU/dL). Patients with lower transfusion requirements within the first 24 h (≤10 units of PRBCs) also had higher admission prothrombin levels compared to patients with massive transfusion demands (>10 units of PRBCs) (95 vs.62 IU/dL). Admission PT, in comparison to admission ROTEM EXTEM CT and MCF, was found to be a better predictor of prothrombin concentration <60 IU/dL (AUC 0.94 in database 1), of massive transfusion (AUC 0.92 and 0.81 in database 1 and 2 respectively) and 24 h mortality (AUC 0.90 and 0.78 in database 1 and 2, respectively). In vitro experiments supported a critical role for prothrombin in coagulation and demonstrated that PT and ROTEM EXTEM CT are sensitive methods to measure low prothrombin concentration.
Our analyses suggest that prothrombin concentration at admission is predictive of mortality and transfusion and indicates that prothrombin and fibrinogen are rate limiting in coagulopathy.
Admission PT is predictive of low prothrombin concentration and clinical outcome. PT could therefore be used as a surrogate for prothrombin concentration and further evaluation of point-of-care devices for faster PT analysis is warranted.
KeywordsProthrombin Coagulopathy Severe bleeding PT ROTEM Biomarker
Hemorrhage is still a common cause of death in trauma. Even when patients are rapidly brought to hospital and are treated according to current trauma guidelines, patients may die because of bleeding that cannot be controlled [1, 2]. Coagulopathy is associated with worse outcomes and may develop during hemorrhage or transfusion therapy [3–5]. Fibrinogen and prothrombin have been suggested to be the first coagulation factors to become rate limiting for coagulation in such situations . While the administration of fibrinogen is now recommended to restore fibrinogen levels [7–9], the importance of prothrombin in trauma-induced coagulopathy and patient outcome is unclear.
In experimental models of dilutional coagulopathy, administration of recombinant human (rh) prothrombin alone or in combination with fibrinogen improved survival, reduced blood loss and improved coagulation when measured by ROTEM and PT [10, 11]. Administration of prothrombin-containing concentrates may therefore be useful also in trauma patients with coagulopathy. Measurement of prothrombin concentration is necessary to identify patients with low levels and address the concern that over supplementation could lead to increased thrombotic risk [12–14]. However, since central lab analyses of plasma samples for prothrombin concentration are too slow, there is a need for surrogate biomarkers to identify patients with low prothrombin concentration. We have therefore conducted analyses of prothrombin levels in a prospective observational cohort from a London Trauma Centre and extended analyses on outcomes in an independent cohort from the Medical University of Innsbruck.
The aims of the study were, firstly, to investigate the consequence of admission prothrombin concentration on massive transfusion (more than 10 PRBC units) and mortality at 24 h. Secondly, to determine the relationship between admission biomarkers (PT, ROTEM EXTEM CT and MCF) and prothrombin concentration, and thirdly, to understand the ability of admission biomarkers to act as a surrogate for low prothrombin concentration and predict outcome. To further evaluate the individual role of prothrombin on PT and ROTEM biomarkers, in vitro studies were performed to investigate the effect of specific prothrombin depletion.
Analyses of prospective observational cohort studies
Database 1 (London) was generated from the Activation of Coagulation & Inflammation in Trauma (ACIT) study, a prospective observational cohort study conducted at the Royal London Hospital, London, UK. Patient samples used in this study were collected between January 2008 and September 2013. The ACIT study was reviewed and approved by the UK Regional Ethics Committee . All adult trauma patients (>15 years) who met the local criteria for full trauma team activation were eligible for enrollment and recruited into the study when research personnel were present (08:00-00:00 daily). Exclusion criteria were: arrival in the emergency department 2 h after injury; the administration of 2000 mL of intravenous fluid before emergency department arrival; transfer from another hospital; and burns covering 5% of the total body surface area. Patients were retrospectively excluded if they declined to give consent to use research samples collected, were found to be taking anticoagulant medications, had moderate or severe liver disease or a known bleeding diathesis.
Database 2 (Innsbruck) was generated from the Diagnosis and Treatment of Trauma-Induced Coagulopathy (DIA-TRE-TIC) study, a single center prospective cohort study conducted at Innsbruck Medical University Hospital between July 2005 and July 2008. Adult poly-trauma patients, who were admitted to the Level I Trauma Center at Innsbruck Medical University Hospital were eligible for enrollment and recruitment into the study. Starting in January 2006, patients with isolated traumatic brain injury were enrolled as well. Severe poly-trauma was defined as an Injury Severity Score (ISS) of ≥15 resulting from injury of at least two body regions. Isolated head injury was defined as a Glasgow Coma Score of ≤14 after blunt head trauma in patients with an Abbreviated Injury Score (AIS) of <3 in any other body region. Exclusion criteria were: patients <18 years, penetrating injuries, admittance to the study hospital later than 12 h after trauma, pre-existing coagulopathy, burn injury, malignant disease, avalanche victims, or exhibition of non-head single trauma. The study protocol was approved by the Ethics Committee of Innsbruck Medical University. The need for written informed consent was waived because study-related blood sampling was judged a minimal-risk intervention and all patients were treated according to routine institutional treatment guidelines .
Data have been collected by each trauma center and locally available methods have been used for sample analyses. Prothrombin concentration for database 1 was measured in the hospitals central lab with a prothrombin clot assay and a pooled normal plasma standard calibrated to an international standard for prothrombin. In both hospitals ROTEM analyses were performed locally to the emergency department, whilst PT was analysed in the hospitals central lab. In order to evaluate the predictive ability of admission coagulation biomarker data under real conditions no attempt was made to monitor variation or standardize sample analyses between hospitals.
The main outcomes considered were prothrombin concentration (IU/dL) measured at admission, total amount of PRBC (units) delivered during the first 24 h, and the proportion survival (%) at 24 h after admission. Three binary variants of these outcomes were also defined: low prothrombin (indicator of concentration <60 IU/dL at admission), massive transfusion (indicator of >10 PRBC units) and mortality at 24 h (indicator of death within the first 24 h). Biomarkers included in analyses were fibrinogen concentration, EXTEM CT, EXTEM MCF and PT, all measured at admission.
The relationship between prothrombin concentration at admission with survival at 24 h and, the amount PRBC delivered during the first 24 h after admission, as well as with fibrinogen concentration, EXTEM CT, EXTEM MCF and PT, was investigated graphically for database 1. Furthermore, Spearman’s correlation coefficient was used to quantify the relationships between prothrombin concentration and fibrinogen concentration, EXTEM CT, EXTEM MCF and PT values. Prothrombin and fibrinogen concentration, EXTEM CT, EXTEM MCF and PT are all admission values.
For each of the three binary outcomes the predictive ability of EXTEM CT, of EXTEM MCF and of PT was assessed using receiver operating characteristic (ROC) analyses. Comparison between EXTEM CT, EXTEM MCF and PT was quantified by the area under the ROC (AUC). DeLong’s test  was used to assess statistical difference between the AUCs. ROC analyses were performed using R package pROC . Graphs and analyses were performed using R version 3.1.0 and above (R Foundation for Statistical Computing, Vienna, Austria). The significance level used was 0.05.
In vitro prothrombin studies
The prothrombin neutralizing anti-human monoclonal antibody AB730006 ba SP14-046 IgG2b was obtained from MedImmune (Cambridge, UK).
Blood samples intended for in vitro studies at AstraZeneca R&D, Gothenburg, Sweden were drawn from 5 healthy volunteers (3 males and 2 females) after informed consent and approval from the local Gothenburg ethical committee (ethical permit number: 033-10). The sample size was not determined from a formal power calculation for this particular study but was based on previous experience of the assay methods used. Whole blood was collected into polypropylene tubes from Sarstedt (Nümbrecht, Germany) by free flow from a 17-gauge Venflon needle from Becton Dickinson Infusion Therapy AB (Helsingborg, Sweden). The first 2 mL of the collected blood was discarded. Then nine volumes blood was mixed with one volume 0.11 M trisodium citrate. Of the 50 mL whole blood collected per donor 10 mL was used for preparation of platelet poor plasma by centrifugation of the citrated blood at 2000 x g in a swing-out rotor for 20 min at 20 °C prior to transfer of the plasma supernatant to a new sample tube.
Clot elasticity was measured by a standard coagulation test (EXTEM + STARTEM reagents, Tem Innovations GmbH, Munich, Germany) using ROTEM equipment (Tem Innovations GmbH). Citrated blood, as described above, was pre-incubated with prothrombin neutralizing anti-human antibody (MedImmune) 0.021, 0.041, 0.062 and 0.083 mg/mL to study the effect of a specific decrease in prothrombin. A serial dilution was also performed to study the effect of a simultaneous decrease in all coagulation and anticoagulation factors. This step-wise dilution was done with 13 mM sodium citrate buffer starting at 100% whole blood and then 70, 50, 40, 30, 20, 10 and 5% whole blood. Samples were kept at 37 °C for 10 min before starting ROTEM analysis. Sodium citrate was included in the dilution buffer to keep the citrate concentration constant during dilution of the citrated whole blood. Thus, the free calcium concentration following addition of calcium for recalcifying purposes as part of the standard assay was kept constant. EXTEM CT and EXTEM MCF were evaluated by adding 300 μL of the incubated blood samples into the ROTEM equipment together with 20 μl EXTEM reagent and 20 μL STARTEM reagent according to the manufacturer instructions. All samples were run for 60 min.
Citrated plasma was pre-incubated with prothrombin neutralizing anti-human antibody (MedImmune) 0.021, 0.041, 0.062, 0.083, 0.124 and 0.165 mg/mL or diluted with 20 mM sodium citrate starting at 100% and then 70, 50, 40, 30, 20, 10 down to 5% plasma and kept at 37 °C for 9 min before PT was measured by adding 25 μL plasma to the KC 10 A micro coagulometer (Amelung, Lemgo, Germany). Dilution with a sodium citrate buffer for ROTEM analysis was performed as described for the diluted whole blood samples although the concentration of citrate had to be increased to compensate for the lack of hematocrit in plasma. After a 1 min incubation period at 37 °C in the coagulometer, 50 μL of Thromborel® S (Siemens Healthcare GmbH, Marburg, Germany) was added and the time to coagulation was measured. Maximum measurement time was 15 min.
Plasma concentration of prothrombin
Prothrombin functional activity was measured in the antibody-treated and diluted blood/plasma samples using a chromogenic prothrombinase end-point method (PI 200040 Rox Prothrombin, Rossix AB, Mölndal, Sweden) and a SPECTRAmax plate reader (Molecular Devices, California, USA). As a standard a recombinant prothrombin preparation calibrated to the NIBSC 98/590 standard was used. One mg prothrombin was found to be equivalent to 8.74 IU. This information was used to calculate IU/dL from the mg/mL result obtained with the prothrombinase assay.
Association of prothrombin concentration with mortality and transfusion demand in patients
Patient characteristics at admission to emergency department, or within 24 h of admission (24 h survival, and ≥1 PRBC). Data shown is median (IQR) unless otherwise stated
n = 358a
n = 331b
Men, n (%)
Time from injury, minutes
Glasgow Coma Score (GCS)
15 (14, 15)
Injury Severity Score
Systolic BP, mmHg
Factor VII, IU/dL
Factor X, IU/dL
24 h survival, n (%)
≥1 PRBC units, n (%)
EXTEM CT, seconds
EXTEM MCF, mm
The characteristics of the two populations differed in injury severity score (ISS: median 13 and 34 in database 1 and 2 respectively), percentage of patients receiving one or more PRBC units (29 and 44%), and also in age, temperature, systolic blood pressure and platelets (Table 1).
Impact of prothrombin concentration on EXTEM CT, EXTEM MCF and PT in vitro
Association of admission prothrombin concentration with PT or EXTEM CT and EXTEM MCF in patients
Assessment of PT, EXTEM MCF and EXTEM CT as predictors of prothrombin concentration and outcome in patients
Summary of ROC analyses
Mortality 24 h
AUC (95% CI) p-value
AUC (95% CI)
AUC (95% CI)
n = 358
0.66 (0.48, 0.82)
n = 331
In order to complete the linkage between PT as a surrogate biomarker for prothrombin concentration, ROC analyses were performed to investigate the ability for PT to predict survival and transfusion demand. Based on database 1, PT was a significantly better predictor of 24 h mortality (AUC 0.90) and of massive transfusion (AUC 0.92) than EXTEM CT or EXTEM MCF (Fig. 4a and Table 2). In database 2, PT was the better predictor and highest AUC for both endpoints, however, the difference between PT and the two other biomarkers was smaller for database 2 (Fig. 4b and Table 2).
In this study we investigated the critical role of prothrombin concentration in coagulopathy and prediction of outcome in coagulopathic trauma patients. In addition, we evaluated currently available coagulation biomarkers as surrogates for detecting critically low plasma prothrombin levels. Data presented indicates that admission prothrombin plasma concentration can be used to predict increased survival and a lower transfusion demand within the first 24 h following admission of the trauma patient and that a cut-off in the range of 50–70 IU/dL at admission is associated with a worse outcome (Fig. 1). During such a coagulopathy many coagulation factors are simultaneously reduced. This has been previously shown where coagulation factors and biomarkers were analysed in coagulopathic patients with INRs of 1.5–3 prior and post FFP administration . Similar to our findings, these patients had a median prothrombin concentration of 34% of normal before FFP administration and also reduced concentrations of several other coagulation factors such as Factor X and fibrinogen.
Since several coagulation factors are reduced in coagulopathic trauma patients we investigated the specific role of prothrombin concentration in coagulation by in vitro experiments. Our in vitro data comparing specific neutralization of prothrombin by a prothrombin neutralizing antibody and general dilution of all coagulation factors by serial dilution of blood or plasma, showed that reduction in prothrombin concentration had a dramatic effect on both PT and ROTEM CT. Comparable data was found for specific neutralization of prothrombin or general dilution of all coagulation factors suggesting that prothrombin concentration is a rate limiting factor in coagulation (Fig. 2). Our in vitro results also support the usefulness of PT and EXTEM CT as surrogate markers for direct measurement of prothrombin concentration. EXTEM MCF is not appropriate due to the discrepancy between ROTEM MCF obtained during step-wise dilution and neutralization of prothrombin. This is thought to be due to that following neutralization a proportion of prothrombin is still activated and is available to activate platelets and fibrinogen which are at normal concentration. Since fibrinogen and platelets are mainly responsible for building MCF the same clot stability is reached eventually. In the case of step-wise dilution, all coagulation factor concentrations and platelet count are decreased and hence the almost linear decrease in EXTEM MCF.
Extending in vitro findings to the trauma databases, prothrombin concentration in trauma patients was also reflected in the biomarkers PT, EXTEM CT and EXTEM MCF. Furthermore, low prothrombin concentration was correlated with a low fibrinogen concentration (Fig. 3). This suggests that the trauma patients having low fibrinogen and prothrombin concentrations are coagulopathic due to coagulation factor consumption and/or dilution. Since point-of-care (PoC) tests are not available for the fast analysis of fibrinogen or prothrombin, surrogate coagulation markers could be used to identify patients with low prothrombin concentrations. The idea of early identification of patients in need of hemostatic therapy by the use of coagulation assays is not new. ROTEM and TEG, where available, are used for this purpose and for guiding therapy [7–9, 20]. In hemorrhagic patients the PT assay has as far as we are aware been used to analyse retrospective data, although it is sometimes used as a tool to confirm the effectiveness of hemostatic therapy .
In the clinic, a cut-off value to define “low prothrombin” is required in order to decide who will receive prothrombin containing treatment and who will not. A cut-off value for prothrombin is also needed for ROC analysis in order to compare the sensitivity and specificity of biomarkers to predict low prothrombin concentration. From Fig. 1, we observed that there appears to be a change in the proportion of survivors and the total amount of administered PBRC within the prothrombin concentration range of 50–70 IU/dL. Furthermore, in vitro data presented in Fig. 2 shows that decreasing prothrombin below a similar limit has a large impact on PT and EXTEM CT. These two observations together provides evidence for a threshold in prothrombin concentration within the range of 50–70 IU/dL that is critical for coagulation. In order to evaluate biomarker predictivity we chose to evaluate 60 IU/dL as a binary threshold for ROC analyses since a prothrombin concentration below 60 IU/dL is considered to be out of the normal range and therefore is reflective of a clinically relevant cut-off.
ROC analyses suggests that PT is a better predictor of low prothrombin concentration versus EXTEM CT and EXTEM MCF. To check how sensitive the biomarker comparisons were to the choice of cut off level, we also performed the analyses using < 70 IU/dL. The ranking of the coagulation biomarkers remained the same independently of whether the cut off was set to < 60 (Fig. 4) or < 70 IU/dL (data not shown). Furthermore, PT was also the better predictor of massive transfusion and mortality compared to EXTEM CT and EXTEM MCF. We chose not to include the amplitudes at 5 or 10 min (A5, A10) in our analyses since they have been shown to correlate well to MCF [22–24]. In the databases analysed even a small increase in PT is associated with an increased risk. This was observed in both independent databases despite multiple differences in the severity of injury and inclusion/exclusion criteria.
We believe that successful normalization of prothrombin levels requires administration of a concentrate such as the recombinant human prothrombin (MEDI8111) that was recently evaluated in healthy volunteers . In support of this, administration of recombinant human prothrombin alone was sufficient to reduce bleeding and improve coagulation and survival time in coagulopathic pigs . In humans, however, the importance of having a sufficiently high fibrinogen concentration has been recognized  and from our database analyses we confirm that there is a strong correlation between admission concentrations of fibrinogen and prothrombin (Fig. 3). We cannot therefore distinguish between the specific contribution of fibrinogen or prothrombin loss alone on prolonged PT and coagulopathy but instead conclude that prothrombin is depleted along with fibrinogen during the development of coagulopathy and that replacement of both factors is required to achieve hemostasis.
PT is a useful biomarker to identify eligible patients for prothrombin replacement therapies although centrally measured PT was used in the current databases which is recognised to have limitations in guiding treatment due to the slow turnaround time . A number of PoC analysers of PT are available e.g. CoaguChek XS system, Roche; i-STAT system, Abbott, and need to be evaluated further for this purpose. If this can be achieved, it seems possible that in the future massive bleedings can be controlled or even avoided by identification of coagulopathic patients depleted in prothrombin by simple available PoC methodology.
This study is based on analyses of two prospective observational cohorts. Since prothrombin concentration was not routinely measured at the Medical University of Innsbruck the number of patients with admission data was limited. All analyses involving prothrombin were therefore restricted to database 1 but database 2 was included and added value by extending observations regarding the predictivity of PT for mortality and transfusion in two independent databases. There are also multiple differences in the databases with regards to severity of injury, inclusion/exclusion criteria, biomarker analyses and importantly admission sampling time from injury. While this variability does add noise to the study we consider that it also adds strength in our conclusions i.e. that despite these differences, PT is still predictive of outcome and the better biomarker in both databases and as a consequence supportive of broader clinical utility.
From this study we conclude that low prothrombin concentration with a cut-off in the range of 50–70 IU/dL (corresponding to approximately 50–70% of normal prothrombin concentration) together with low fibrinogen is rate limiting for coagulation in bleeding trauma patients and is associated with an increased risk for massive transfusion and mortality. PT at admission is a sensitive and specific predictor of low prothrombin concentration and is a better predictor of massive transfusion and mortality than the ROTEM parameters EXTEM CT and EXTEM MCF used for current guidance.
Fresh frozen plasma
International Normalized Ratio
Injury severity score
Maximum clot firmness
Point of care
Packed red blood cells
Receiver operating characteristic (curve)
The authors gratefully acknowledge the technical assistance of Dr. Philipp Würtinger for the recalculation of PT/INR data in the Innsbruck database.
Analyses of data previously generated through ACIT and DIA-TRE-TIC studies was funded by AstraZeneca R&D Gothenburg, Sweden.
Availability of data and materials
All data generated or analysed during this study are included in this published article.
AL drafted the manuscript and advised experimental design, CB contributed to experimental design, interpretation of the results and writing of the manuscript, KH advised experimental design and evaluation of results, designed and evaluated in vitro experiments and participated in manuscript writing, MO and KN performed statistical analyses, interpreted results and participated in manuscript writing, KJ performed and evaluated in vitro experiments and participated in writing of manuscript, AB advised experimental design and evaluation of results and participated in manuscript writing. KB and DF provided clinical and biomarker data in the respective London and Innsbruck databases and contributed to interpretation of the results and review of the manuscript. All authors read and approved the final manuscript.
AL is a former employee of AstraZeneca. AB, KH, CB, KN, MO and KJ are employees of AstraZeneca, Sweden. DF is an Associate Professor at Medical University Innsbruck, Austria and KB is a Professor of Trauma Sciences at Queen Mary, University of London, United Kingdom.
Analyses of biomarker data within the London and Innsbruck prospective cohort studies was sponsored by AstraZeneca. TEM International GMbH (Munich Germany) provided ROTEM reagents and equipment on an unrestricted basis to KB. DF and KB have received honoraria from AstraZeneca and others for consultancy. CB, AL, KH, KN, MO, KJ and AB declare no competing interests.
Consent for publication
Ethics approval and consent to participate
The ACIT study was reviewed and approved by the UK Regional Ethics Committee . Patients were retrospectively excluded if they declined to give consent to use research samples collected.
The DIA-TRE-TIC study was approved by the Ethics Committee of Innsbruck Medical University. The need for written informed consent was waived because study-related blood sampling was judged a minimal-risk intervention and all patients were treated according to routine institutional treatment guidelines .
Blood samples intended for in vitro studies were drawn from healthy volunteers at AstraZeneca R&D, Gothenburg, Sweden after informed consent and approval from the local Gothenburg ethical committee (ethical permit number: 033-10).
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Pfeifer R, Tarkin IS, Rocos B, Pape HC. Patterns of mortality and causes of death in polytrauma patients—has anything changed? Injury. 2009;40:907–11.View ArticlePubMedGoogle Scholar
- O’Reilly D, Mahendran K, West A, Shirley P, Walsh M, Tai N. Opportunities for improvement in the management of patients who die from haemorrhage after trauma. Br j surg. 2013;100:749–55.View ArticlePubMedGoogle Scholar
- Frith D, Davenport R, Brohi K. Acute traumatic coagulopathy. Curr opin anaesthesiol. 2012;25:229–34.View ArticlePubMedGoogle Scholar
- Brohi K, Singh J, Heron M, Coats T. Acute traumatic coagulopathy. J trauma. 2003;54:1127–30.View ArticlePubMedGoogle Scholar
- Hunt BJ. Bleeding and coagulopathies in critical care. N engl j med. 2014;370:847–59.View ArticlePubMedGoogle Scholar
- Hiippala ST, Myllyla GJ, Vahtera EM. Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates. Anesth analg. 1995;81:360–5.PubMedGoogle Scholar
- Rossaint R, Bouillon B, Cerny V, Coats TJ, Duranteau J, Fernandez-Mondejar E, et al. Management of bleeding following major trauma: an updated European guideline. Crit care. 2010;14:R52.View ArticlePubMedPubMed CentralGoogle Scholar
- Spahn DR, Bouillon B, Cerny V, Coats TJ, Duranteau J, Fernandez-Mondejar E, et al. Management of bleeding and coagulopathy following major trauma: an updated European guideline. Crit care. 2013;17:R76.View ArticlePubMedPubMed CentralGoogle Scholar
- Rossaint R, Bouillon B, Cerny V, Coats TJ, Duranteau J, Fernandez-Mondejar E, et al. The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition. Crit care. 2016;20:100. 016-1265-x.View ArticlePubMedPubMed CentralGoogle Scholar
- Mitterlechner T, Innerhofer P, Streif W, Lodl M, Danninger T, Klima G, et al. Prothrombin complex concentrate and recombinant prothrombin alone or in combination with recombinant factor X and FVIIa in dilutional coagulopathy: a porcine model. J thromb haemost. 2011;9:729–37.View ArticlePubMedGoogle Scholar
- Hansson KM, Johansson KJ, Wingren C, Fries D, Nelander K, Lövgren A. Recombinant human prothrombin reduced blood loss in a porcine model of dilutional coagulopathy with uncontrolled bleeding. Blood Coagul Fibrinolysis. 2016;DOI: 10.1097/MBC.0000000000000590.
- Kohler M. Thrombogenicity of prothrombin complex concentrates. Thromb res. 1999;95:S13–7.View ArticlePubMedGoogle Scholar
- Sorensen B, Spahn DR, Innerhofer P, Spannagl M, Rossaint R. Clinical review: prothrombin complex concentrates—evaluation of safety and thrombogenicity. Crit care. 2011;15:201.View ArticlePubMedPubMed CentralGoogle Scholar
- Quick JA, Meyer JM, Coughenour JP, Barnes SL. Less is more: Low-dose prothrombin complex concentrate effective in acute care surgery patients. Am surg. 2015;81:646–50.PubMedGoogle Scholar
- Raza I, Davenport R, Rourke C, Platton S, Manson J, Spoors C, et al. The incidence and magnitude of fibrinolytic activation in trauma patients. J thromb haemost. 2013;11:307–14.View ArticlePubMedGoogle Scholar
- Tauber H, Innerhofer P, Breitkopf R, Westermann I, Beer R, El Attal R, et al. Prevalence and impact of abnormal ROTEM(R) assays in severe blunt trauma: results of the ‘diagnosis and treatment of trauma-induced coagulopathy (DIA-TRE-TIC) study’. Br j anaesth. 2011;107:378–87.View ArticlePubMedGoogle Scholar
- Delong ER, Delong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837–45.View ArticlePubMedGoogle Scholar
- Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC bioinformatics. 2011;12:77. 2105-12-77.View ArticlePubMedPubMed CentralGoogle Scholar
- Muller MC, Straat M, Meijers JC, Klinkspoor JH, de Jonge E, Arbous MS, et al. Fresh frozen plasma transfusion fails to influence the hemostatic balance in critically ill patients with a coagulopathy. J thromb haemost. 2015;13:989–97.View ArticlePubMedGoogle Scholar
- Schochl H, Nienaber U, Hofer G, Voelckel W, Jambor C, Scharbert G, et al. Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM)-guided administration of fibrinogen concentrate and prothrombin complex concentrate. Crit care. 2010;14:R55.View ArticlePubMedPubMed CentralGoogle Scholar
- Rujirojindakul P, Rujirojindakul P, Mcneil EB, Geater AF, Chanchayanon T, Sangthong B, et al. Prediction score for effective bleeding control using recombinant activated factor VII in perioperative nonhemophilic patients. Am j surg. 2013;206:326–32.View ArticlePubMedGoogle Scholar
- Meyer AS, Meyer MA, Sorensen AM, Rasmussen LS, Hansen MB, Holcomb JB, et al. Thrombelastography and rotational thromboelastometry early amplitudes in 182 trauma patients with clinical suspicion of severe injury. J trauma acute care surg. 2014;76:682–90.View ArticlePubMedGoogle Scholar
- Dirkmann D, Gorlinger K, Dusse F, Kottenberg E, Peters J. Early thromboelastometric variables reliably predict maximum clot firmness in patients undergoing cardiac surgery: a step towards earlier decision making. Acta anaesthesiol scand. 2013;57:594–603.View ArticlePubMedGoogle Scholar
- Gorlinger K, Dirkmann D, Solomon C, Hanke AA. Fast interpretation of thromboelastometry in non-cardiac surgery: reliability in patients with hypo-, normo-, and hypercoagulability. Br j anaesth. 2013;110:222–30.View ArticlePubMedGoogle Scholar
- To Assess Safety, Tolerability and Pharmacodynamics of Intravenous MEDI8111 After Single Ascending Doses [Internet].; 2015 . Available from: https://www.clinicaltrials.gov/ct2/show/NCT01958645?term=medi8111&rank=1. Accessed 22 Nov 2016.
- Davenport R, Manson J, De’ath H, Platton S, Coates A, Allard S, et al. Functional definition and characterization of acute traumatic coagulopathy. Crit care med. 2011;39:2652–8.View ArticlePubMedPubMed CentralGoogle Scholar